ArticleTherapeutics and clinical risk management2008
Evaluation of extended and continuous use oral contraceptives.
Article in Therapeutics and clinical risk management, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Development of breakthrough bleeding model of combined-oral contraceptives utilizing model-based meta-analysis.CPT: pharmacometrics & systems pharmacology · 2024Pooled it
- Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study.The journal of family planning and reproductive health care · 2013Trial
- Cardiometabolic Risk Factors in Women Exposed to High Altitude.International journal of molecular sciences · 2026Review
- How We Can Optimize Dysmenorrhea Treatment: Real-World Results from a Cross-Sectional, Multi-Center Study.Geburtshilfe und Frauenheilkunde · 2026Article
- The Menstrual Health Manager (MHM): A Resource to Reduce Discrepancies Between Science and Practice in Sport and Exercise.Sports medicine (Auckland, N.Z.) · 2024Article
- Experts' view on the role of oestrogens in combined oral contraceptives: emphasis on oestetrol (E4).Frontiers in global women's health · 2024Article
- Lower levels of the neuroprotective tryptophan metabolite, kynurenic acid, in users of estrogen contraceptives.Scientific reports · 2023Article
- Management of a Patient With Premenstrual Syndrome Using Acupuncture, Supplements, and Meditation: A Case Report.Journal of chiropractic medicine · 2023Article
- Equipping providers to offer novel MPTs: Developing counseling messages for the Dual Prevention Pill in clinical studies and beyond.Frontiers in reproductive health · 2023Review
- Medication Adherence Reminder System for Virtual Home Assistants: Mixed Methods Evaluation Study.JMIR formative research · 2021Article
- Plasma Homoarginine Concentrations According to Use of Hormonal Contraception.Scientific reports · 2018Article
- Early Endometriosis in Females Is Directed by Immune-Mediated Estrogen Receptor α and IL-6 Cross-Talk.Endocrinology · 2018Article
- High prevalence of pain among adult HIV-infected patients at University of Gondar Hospital, Northwest Ethiopia.Journal of pain research · 2017Article
- Contraceptive challenges in adolescents living with or at risk of HIV.Journal of virus eradication · 2016Article
- The lowest-dose, extended-cycle combined oral contraceptive pill with continuous ethinyl estradiol in the United States: a review of the literature on ethinyl estradiol 20 μg/levonorgestrel 100 μg + ethinyl estradiol 10 μg.International journal of women's health · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral contraceptives are classically given in a cyclic manner with 21 days of active pills followed by 7 days of placebo. In the past 4 years, new oral contraceptives have been introduced which either shorten the placebo time, lengthen the active pills (extended cycle), or provide active pills every day (continuous). These concepts are not new; extended and continuous pills were first studied in the 1960s and 1970s and have been provided in an off-label manner by gynecologists to treat menstrual disorders, such as menorrhagia and dysmenorrhea, and gynecologic disorders, such as endometriosis. Now that extended and continuous combined oral contraceptives are available for all patients, it is critical for providers to understand the physiology, dosing, side effects, and benefits of this form of oral contraceptive. This article reviews the history and the potential uses of the new continuous combined oral contraceptive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.